Stoke Therapeutics (STOK) Cash & Current Investments (2018 - 2026)

Stoke Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $343.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 3.86% year-over-year to $343.5 million; the TTM figure through Mar 2026 stood at $343.5 million (down 3.86% YoY), while the FY2025 annual figure was $284.7 million, up 31.25% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $343.5 million, up from $284.7 million in the prior quarter.
• The five-year high for Cash & Current Investments was $357.3 million in Q1 2025, with the low at $150.1 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $247.7 million (2025), against an average of $245.4 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments sank 30.1% in 2024, then jumped 100.09% in 2025.
• Stoke Therapeutics' Cash & Current Investments stood at $229.6 million in 2022, then decreased by 12.28% to $201.4 million in 2023, then advanced by 7.7% to $216.9 million in 2024, then soared by 31.25% to $284.7 million in 2025, then gained by 20.68% to $343.5 million in 2026.
• Business Quant data shows STOK's Cash & Current Investments at $343.5 million in Q1 2026, $284.7 million in Q4 2025, and $248.3 million in Q3 2025.